Enhancing Radiotherapy for Melanoma: the Promise of High-Z Metal Nanoparticles in Radiosensitization

Overview

Journal Nanomedicine (Lond)

Specialty Biotechnology

Date 2024 Oct 9

PMID 39382020

Authors

Abolfazl Bemidinezhad

Shaghayegh Radmehr

Negin Moosaei

Zohreh Efati

Prashant Kesharwani

Amirhossein Sahebkar

Affiliations

Soon will be listed here.

Abstract

Melanoma is a type of skin cancer that can be challenging to treat, especially in advanced stages. Radiotherapy is one of the main treatment modalities for melanoma, but its efficacy can be limited due to the radioresistance of melanoma cells. Recently, there has been growing interest in using high-Z metal nanoparticles (NPs) to enhance the effectiveness of radiotherapy for melanoma. This review provides an overview of the current state of radiotherapy for melanoma and discusses the physical and biological mechanisms of radiosensitization through high-Z metal NPs. Additionally, it summarizes the latest research on using high-Z metal NPs to sensitize melanoma cells to radiation, both and . By examining the available evidence, this review aims to shed light on the potential of high-Z metal NPs in improving radiotherapy outcomes for patients with melanoma.

References

Malam Y, Loizidou M, Seifalian A . Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30(11):592-9. DOI: 10.1016/j.tips.2009.08.004. View

Otsuka H, Nagasaki Y, Kataoka K . PEGylated nanoparticles for biological and pharmaceutical applications. Adv Drug Deliv Rev. 2003; 55(3):403-19. DOI: 10.1016/s0169-409x(02)00226-0. View

Xu W, Luo T, Li P, Zhou C, Cui D, Pang B . RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating α(v)β₃ expression. Int J Nanomedicine. 2012; 7:915-24. PMC: 3299204. DOI: 10.2147/IJN.S28314. View

Akhter S, Ahmad M, Ahmad F, Storm G, Kok R . Gold nanoparticles in theranostic oncology: current state-of-the-art. Expert Opin Drug Deliv. 2012; 9(10):1225-43. DOI: 10.1517/17425247.2012.716824. View

de Jong W, Borm P . Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008; 3(2):133-49. PMC: 2527668. DOI: 10.2147/ijn.s596. View

Trott K . The optimal radiation dose per fraction for the treatment of malignant melanomas. Int J Radiat Oncol Biol Phys. 1991; 20(4):905-7. DOI: 10.1016/0360-3016(91)90041-2. View

Chandra R, Wilhite T, Balboni T, Alexander B, Spektor A, Ott P . A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology. 2015; 4(11):e1046028. PMC: 4589983. DOI: 10.1080/2162402X.2015.1046028. View

Gong L, Zhang Y, Liu C, Zhang M, Han S . Application of Radiosensitizers in Cancer Radiotherapy. Int J Nanomedicine. 2021; 16:1083-1102. PMC: 7886779. DOI: 10.2147/IJN.S290438. View

Dai Q, Walkey C, Chan W . Polyethylene glycol backfilling mitigates the negative impact of the protein corona on nanoparticle cell targeting. Angew Chem Int Ed Engl. 2014; 53(20):5093-6. DOI: 10.1002/anie.201309464. View

10.

Duval K, Vernice N, Wagner R, Fiering S, Petryk J, Lowry G . Immunogenetic effects of low dose (CEM43 30) magnetic nanoparticle hyperthermia and radiation in melanoma cells. Int J Hyperthermia. 2019; 36(sup1):37-46. PMC: 6943912. DOI: 10.1080/02656736.2019.1627433. View

11.

Choi J, Kim G, Cho S, Im H . Radiosensitizing high-Z metal nanoparticles for enhanced radiotherapy of glioblastoma multiforme. J Nanobiotechnology. 2020; 18(1):122. PMC: 7470617. DOI: 10.1186/s12951-020-00684-5. View

12.

Muringayil Joseph T, Mahapatra D, Esmaeili A, Piszczyk L, Hasanin M, Kattali M . Nanoparticles: Taking a Unique Position in Medicine. Nanomaterials (Basel). 2023; 13(3). PMC: 9920911. DOI: 10.3390/nano13030574. View

13.

Marin A, Martin M, Linan O, Alvarenga F, Lopez M, Fernandez L . Bystander effects and radiotherapy. Rep Pract Oncol Radiother. 2014; 20(1):12-21. PMC: 4268598. DOI: 10.1016/j.rpor.2014.08.004. View

14.

Lin W, Huang Y, Zhou X, Ma Y . In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006; 217(3):252-9. DOI: 10.1016/j.taap.2006.10.004. View

15.

Salvati A, Pitek A, Monopoli M, Prapainop K, Bombelli F, Hristov D . Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol. 2013; 8(2):137-43. DOI: 10.1038/nnano.2012.237. View

16.

Peltek O, Karpov T, Rogova A, Postovalova A, Ageev E, Petrov A . Development of Nanocarrier-Based Radionuclide and Photothermal Therapy in Combination with Chemotherapy in Melanoma Cancer Treatment. ACS Appl Mater Interfaces. 2023; 15(10):13460-13471. DOI: 10.1021/acsami.2c20619. View

17.

Rogosnitzky M, Branch S . Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29(3):365-76. PMC: 4879157. DOI: 10.1007/s10534-016-9931-7. View

18.

Pucci C, DeglInnocenti A, Belenli Gumus M, Ciofani G . Superparamagnetic iron oxide nanoparticles for magnetic hyperthermia: recent advancements, molecular effects, and future directions in the omics era. Biomater Sci. 2022; 10(9):2103-2121. DOI: 10.1039/d1bm01963e. View

19.

Kim S, Kim S, Han S, Lee S, Park H, Song J . Molecular Mechanism and Prevention Strategy of Chemotherapy- and Radiotherapy-Induced Ovarian Damage. Int J Mol Sci. 2021; 22(14). PMC: 8305189. DOI: 10.3390/ijms22147484. View

20.

Bort G, Lux F, Dufort S, Cremillieux Y, Verry C, Tillement O . EPR-mediated tumor targeting using ultrasmall-hybrid nanoparticles: From animal to human with theranostic AGuIX nanoparticles. Theranostics. 2020; 10(3):1319-1331. PMC: 6956799. DOI: 10.7150/thno.37543. View